Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BVEC for Squamous Cell Carcinoma Recurrence in RDEB
NCT06731933Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of beremagene geperpavec in squamous cell carcinoma (SCC), sponsored by Stanford University. Started Mar 2025; status: recruiting.
02
Drugs
beremagene geperpavec
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT06731933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731933.